Wolfgang W Fleischhacker
Overview
Explore the profile of Wolfgang W Fleischhacker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
429
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levi L, Bar-Haim M, Rossum I, Davidson M, Leucht S, Fleischhacker W, et al.
Schizophr Bull
. 2023 Mar;
49(4):903-913.
PMID: 36999551
Background And Hypothesis: This analysis examined the relationship between cannabis use, compliance with antipsychotics and risk for relapse in patients in remission following a first episode of schizophrenia, schizophreniform, or...
2.
Baandrup L, Allerup P, Nielsen M, During S, Bojesen K, Leucht S, et al.
Acta Psychiatr Scand
. 2022 Apr;
146(1):21-35.
PMID: 35417039
Objective: Historically, assessment of the psychometric properties of the Positive and Negative Syndrome Scale (PANSS) has had several foci: (1) calculation of reliability indexes, (2) extraction of subdimensions from the...
3.
Kurzthaler I, Kemmler G, Defrancesco M, Moser B, Fleischhacker W, Weiss E
Pharmacopsychiatry
. 2017 Jun;
50(5):203-210.
PMID: 28641332
The purpose of this study was to elucidate the impact of specific cognitive functions on self-restricted driving habits in healthy elderly drivers and patients suffering from mild cognitive impairment (MCI)...
4.
Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker W, Garibaldi G, Wang A, et al.
Biol Psychiatry
. 2017 Jan;
82(1):8-16.
PMID: 28117049
Background: There is currently no standard of care for treatment of negative symptoms of schizophrenia, although some previous results with glutamatergic agonists have been promising. Methods: Three (SunLyte [WN25308], DayLyte...
5.
Koutsouleris N, Kahn R, Chekroud A, Leucht S, Falkai P, Wobrock T, et al.
Lancet Psychiatry
. 2016 Aug;
3(10):935-946.
PMID: 27569526
Background: At present, no tools exist to estimate objectively the risk of poor treatment outcomes in patients with first-episode psychosis. Such tools could improve treatment by informing clinical decision-making before...
6.
Savitz A, Xu H, Gopal S, Nuamah I, Ravenstijn P, Janik A, et al.
Int J Neuropsychopharmacol
. 2016 Feb;
19(7).
PMID: 26902950
Background: This double-blind, parallel-group, multicenter, phase-3 study was designed to test the noninferiority of paliperidone palmitate 3-month formulation (PP3M) to the currently marketed 1-month formulation (PP1M) in patients (age 18-70...
7.
Hoertnagl C, Yalcin-Siedentopf N, Baumgartner S, Biedermann F, Deisenhammer E, Hausmann A, et al.
Schizophr Res
. 2014 Aug;
158(1-3):100-4.
PMID: 25096540
Affect perception has frequently been shown to be impaired in patients suffering from schizophrenia or bipolar disorder (BD), but it remains unclear whether these impairments exist during symptomatic remission and...
8.
Marques T, Levine S, Reichenberg A, Kahn R, Derks E, Fleischhacker W, et al.
Eur Neuropsychopharmacol
. 2014 May;
24(8):1279-88.
PMID: 24862257
The clinical expression of schizophrenia is generally reported to be expressed by three to five different factors (i.e. positive, negative, disorganization, excitability, anxiety-depression symptoms). It is often claimed that antipsychotic...
9.
Emsley R, Fleischhacker W
Schizophr Res
. 2013 Oct;
150(2-3):427-33.
PMID: 24094881
Background: Placebo-controlled randomised controlled trials (RCTs) continue to be required or recommended by regulatory authorities for the licensing of new drugs for schizophrenia, despite ongoing concerns regarding the risks to...
10.
Park M, Han C, Pae C, Lee S, Patkar A, Masand P, et al.
Expert Rev Neurother
. 2011 Oct;
11(11):1541-52.
PMID: 22014131
The most current treatment guidelines for schizophrenia recommend more than 1 year of maintenance therapy after the first psychotic episode, and more than 5 years of maintenance therapy after multiple...